Procaps Group, S.A. (PROC) |
|
7.7008 0.201 (2.68%)
|
05-16 01:38 |
|
Open: |
7.7008 |
Pre. Close: |
7.5 |
|
High:
|
7.76 |
Low:
|
7.24 |
|
Volume:
|
239 |
Market Cap:
|
869(M) |
|
|
|
|
Procaps Group, S.A. operates as an integrated healthcare and pharmaceutical company worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately ten therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg City, Luxembourg. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.77 - 7.8 |
7.8 - 7.84 |
|
Low:
|
7.15 - 7.19 |
7.19 - 7.23 |
|
Close:
|
7.63 - 7.7 |
7.7 - 7.76 |
|
Technical analysis |
as of: 2022-05-13 4:40:43 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 9.99  One year: 11.67 |
| Support: |
Support1: 7.28 Support2: 6.5 |
| Resistance: |
Resistance1: 8.56 Resistance2: 9.99 |
| Pivot: |
7.73  |
| Moving Average: |
MA(5): 7.51 MA(20): 7.82
MA(100): 8.73 MA(250): 9.48 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 53.2 %D(3): 45.4 |
| RSI: |
RSI(14): 45.2 |
| 52-week: |
High: 11.97 Low: 6.5 |
| Average Vol(K): |
3-Month: 39 (K) 10-Days: 23 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PROC ] has closed above bottom band by 47.2%. Bollinger Bands are 2.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Fri, 13 May 2022
Comelec to also limit attendance during PL proc - Manila Bulletin
Mon, 28 Feb 2022
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles - pnas.org
Mon, 28 Feb 2022
Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample - pnas.org
Mon, 28 Feb 2022
Community structure in social and biological networks - pnas.org
Thu, 03 Feb 2022
Faulkner v. Broadway Festivals, Inc., Adv. Proc. 20-05031 (Bankr. N.D. – Tex., January 11, 2022) - JD Supra
Mon, 31 Jan 2022
List of automatic tax method changes updated - Journal of Accountancy
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
113 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
86.7 (%) |
|
% Held by Institutions
|
5.6 (%) |
|
Shares Short
|
485 (K) |
|
Shares Short P.Month
|
480 (K) |
Stock Financials |
|
EPS
|
-5.22 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-127.67 |
|
Profit Margin (%)
|
-11.3 |
|
Operating Margin (%)
|
17.7 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
34.7 |
|
Gross Profit (p.s.)
|
1.69 |
|
Sales Per Share
|
3.55 |
|
EBITDA (p.s.)
|
0.72 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
35 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-1.48 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-0.07 |
|
Price to Sales
|
2.16 |
|
Price to Cash Flow
|
25.09 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
